je.st
news
Tag: cancer patients
Data Investigating KEYTRUDA (pembrolizumab), Mercks Anti-PD-1 Therapy, in Patients with Advanced Triple-Negative Breast Cancer Presented at 2014 San Antonio Breast Cancer Symposium
2014-12-10 14:30:00| Merck.com - Corporate News
Dateline City: SAN ANTONIO 18.5 Percent Overall Response Rate Observed in KEYTRUDA-Treated Patients with This Aggressive Form of Breast Cancer Phase 2 Study Planned for the First Half of 2015 (KEYNOTE-086) SAN ANTONIO--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today early study findings demonstrating an overall response rate of 18.5 percent with KEYTRUDA, the companys anti-PD-1 therapy, as assessed by RECIST v1.1, central review (n=5/27), in PD-L1 positive, advanced triple-negative breast cancer one of the most aggressive forms of breast cancer. Language: English Contact: MerckMedia:Pamela Eisele, (267) 305-3558Claire Mulhearn, (908) 236-1118orInvestor:Joseph Romanelli, (908) 740-1986Justin Holko, (908) 740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: data
advanced
san
presented
Hormel Provides Cancer Patients with Nutritional Offerings
2014-11-15 13:55:57| Food - Topix.net
The specialty foods division of Hormel Foods Corp., Austin, Minn., partnered with the Cancer Nutrition Consortium, West Palm Beach, Fla., to provide cancer patients with nutritional offerings for their specific individual needs during cancer treatment. The Cancer Nutrition Consortium is an innovative collaboration among some of the most notable cancer centers, chefs and nutritional experts focusing on nutritional concerns of patients undergoing cancer treatment.
Tags: cancer
patients
offerings
nutritional
Dutch Cancer Patients to Benefit from Erasmus Medical Center's New Treatment Technology
2014-06-02 06:00:00| Industrial Newsroom - All News for Today
Largest medical center in the Netherlands upgrades with several Elekta Versa HD linear accelerators<br /> <br /> ROTTERDAM, the Netherlands — Clinicians at the Erasmus University Medical Center (Erasmus MC) in Rotterdam, the Netherlands, will be able to offer patients the most modern cancer treatment available through its purchase of Elekta Versa HD™ linear accelerators (linacs) and a substantial software upgrade including Elekta's MOSAIQ® oncology information system and Monaco® 5 ...This story is related to the following:SoftwareSearch for suppliers of: Planning Software |
Tags: technology
medical
treatment
benefit
First Austrian Cancer Patients Receive Treatments on Advanced Elekta Versa HD Radiation ...
2014-04-02 06:00:00| Industrial Newsroom - All News for Today
In complex cases, Medical University Innsbruck clinicians exploit speed and accuracy advantages of new groundbreaking linear accelerator<br /> <br /> INNSBRUCK, Austria – Medical University Innsbruck is the first center in Austria to begin treating patients with Elekta's Versa HD™, a radiation therapy system equipped with advanced beam-shaping and high dose rate technologies to deliver extremely precise treatments in shorter treatment times. Since January 14, the clinic has put 55 ...This story is related to the following:Automatic IDSearch for suppliers of: Radio Frequency Identification (RFID) Systems |
Tags: advanced
receive
cancer
patients
Patient's Death Halts Cancer Drug Trial
2013-11-07 14:51:25| Biotech - Topix.net
A phase I study of an investigational oral inhibitor of apoptosis antagonist, CUDC-427, has been placed on partial clinical hold by the FDA following the death of a patient who had progressed to liver failure approximately 1 month after the discontinuation of CUDC-427 dosing.